Inhibitors of plasmodial serine hydroxymethyltransferase (SHMT): cocrystal structures of pyrazolopyrans with potent blood- and liver-stage activities (Publications)
plausible explanation for lack of significant activity of the inhibitors in the in vivo Pb mouse malaria model
Inhibitors of plasmodial serine hydroxymethyltransferase (SHMT): cocrystal structures of pyrazolopyrans with potent blood- and liver-stage activities (Publications)
plausible explanation for lack of significant activity of the inhibitors in the in vivo Pb mouse malaria model
Antimalarial benzoheterocyclic 4-aminoquinolines: structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies (Publications)
for antiplasmodial activity against K1 (multidrug resistant) and NF54 (sensitive) strains of the malaria parasite Plasmodium falciparum. Structure-activity relationship studies led to the identification
Synthesis and in vitro and in vivo evaluation of antimalarial polyamines (Publications)
falciparum. In an effort to expand the structure-activity relationship of this compound class towards malaria, we have prepared and biologically tested a library that includes benzamide and 3-phenylpropanamide
Open source drug discovery: highly potent antimalarial compounds derived from the Tres Cantos arylpyrroles (Publications)
The development of new antimalarial compounds remains a pivotal part of the strategy for malaria elimination. Recent large-scale phenotypic screens have provided a wealth of potential starting points for
Conformational aspects in the design of inhibitors for serine hydroxymethyltransferase (SHMT): biphenyl, aryl sulfonamide, and aryl sulfone motifs (Publications)
Malaria remains a major threat to mankind due to the perpetual emergence of resistance against marketed drugs. Twenty-one pyrazolopyran-based inhibitors bearing terminal biphenyl, aryl sulfonamide, or
A <em>Plasmodium </em>membrane receptor platform integrates cues for egress and invasion in blood forms and activation of transmission stages (Publications)
Critical events in the life cycle of malaria-causing parasites depend on cyclic guanosine monophosphate homeostasis by guanylyl cyclases (GCs) and phosphodiesterases, including merozoite egress or invasion
TKK130 is a 3-hydroxy-propanamidine (HPA) with potent antimalarial <em>in vivo</em> activity and a high barrier to resistance (Publications)
Malaria continues to pose a significant burden on populations in endemic areas and requires innovative treatment options. Here, we report the synthesis and preclinical evaluation of the novel 3-hydrox
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <em>Plasmodium falciparum</em> parasite resistance (Publications)
mode of action. This preclinical candidate may offer the potential for a single low-dose cure for malaria.
Medical Services (Page)
https://www.swisstph.ch/fr/about/dir/medical-services
and, on behalf of the Federal Office of Public Health (FOPH), provides reference diagnosis for malaria and confirmatory diagnosis for other non-endemic parasitic diseases as part of the surveillance concept